MedTrace Logo

Effectiveness of Mass Drug Administration for Reducing Seasonal Malaria Transmission in Zanzibar

NCT02721186 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 22500

Last updated 2017-10-05

No results posted yet for this study

Summary

The overall aim of this study is to determine the effectiveness of two rounds of mass drug administration (MDA) with dihydroartemisinin-piperaquine (DHAp) + single low dose (SLD) primaquine for reducing seasonal malaria transmission in Shehias considered hotspots on Unguja Island, Zanzibar.

Conditions

Interventions

DRUG

MDA with DHAp and SLD Primaquine

Sponsors & Collaborators

  • Mahidol Oxford Tropical Medicine Research Unit

    collaborator OTHER

  • RTI International

    collaborator OTHER

  • The President's Malaria Initiative

    collaborator UNKNOWN

  • University of California, San Francisco

    collaborator OTHER

  • Uppsala University

    collaborator OTHER

  • Zanzibar Malaria Elimination Programme

    collaborator OTHER_GOV

  • Ulrika Morris

    lead OTHER

Principal Investigators

  • Anders Björkman, MD, PhD · Karolinska Institutet

  • Abdullah S Ali, Programme Manager · Zanzibar Malaria Elimination Programme

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
6 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2016-12-31
Completion
2017-09-30

Countries

  • Tanzania

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02721186 on ClinicalTrials.gov